Supplementary

Table S1 Unscheduled emergency department visits during durvalumab treatment for original and PSM cohorts where stage group level "UNK/MISSING" is excluded

Cohort	Dosing	Crude event rate per 100 person-months (95% CI)	Model	RR (95% CI)	P value
Original cohort	EXT	5.0 (3.3, 7.4)	Crude Model	1.75 (0.80, 3.80)	0.16
	STD	3.6 (2.6, 4.9)	Adjusted Model[†]	1.51 (0.54, 4.23)	0.44
PSM cohort	EXT	5.1 (2.6, 10.2)	Matched Model[‡]	1.96 (0.75, 5.08)	0.17
	STD	4.6 (3.1, 6.9)	Adjusted Model[†]	2.44 (0.68, 8.74)	0.17

[†] Adjusted for health region. [‡] Matched on age, sex, weight, BMI group, income, rurality, ON-Marginalization, Charlson comorbidity index, COPD-specific comorbidity, ECOG status, staging, tumor histologic type, previous NSCLC diagnosis, previous non-NSCLC diagnosis, time from diagnosis to the first durvalumab, time from the last radiotherapy to the first durvalumab, sum dose of previous radiotherapy, time from the last chemotherapy to the first durvalumab, and previous chemotherapy type.

Table S2 Hospital encounters during durvalumab treatment for original and PSM cohorts where stage group level "UNK/MISSING" is excluded

Cohort	Dosing	Crude event rate per 100 person-months (95% CI)	Model	RR (95% CI)	P value
Original cohort	EXT	2.5 (0.9, 6.8)	Crude Model	0.83 (0.27, 2.52)	0.74
	STD	2.4 (1.1, 5.5)	Adjusted Model[†]	1.56 (0.17, 14.65)	0.70
PSM cohort	EXT	2.3 (0.8, 6.5)	Matched Model[‡]	0.52 (0.12, 2.29)	0.38
	STD	2.7 (1.3, 5.5)	Adjusted Model[†]	0.51 (0.03, 9.83)	0.65

[†] Adjusted for health region. [‡] Matched on age, sex, weight, BMI group, income, rurality, ON-Marginalization, Charlson comorbidity index, COPD-specific comorbidity, ECOG status, staging, tumor histologic type, previous NSCLC diagnosis, previous non-NSCLC diagnosis, time from diagnosis to the first durvalumab, time from the last radiotherapy to the first durvalumab, sum dose of previous radiotherapy, time from the last chemotherapy to the first durvalumab, and previous chemotherapy type.

Table S3 Baseline characteristics for combined switching group and extended dosing group

Baseline characteristics	Category	Original cohort			PSM cohort			Standardized difference
		EXT (N=248)	STD COMB (N=494)	P value	EXT (N=224)	STD COMB (N=224)	P value	
Age at first durvalumab (yrs), mean (SD)		67.4 (8.2)	67.4 (8.2)	0.94	67.5 (8.0)	66.7 (7.4)	0.27	0.10
Sex, n (%)	Female	112 (45.2%)	218 (44.1%)	0.79	99 (44.2%)	99 (44.2%)	1.00	0.00
	Male	136 (54.8%)	221 (55.9%)		125 (55.8%)	125 (55.8%)		
Height (cm), mean (SD)		166.9 (9.3)	167.3 (9.0)	0.59	167.0 (9.3)	166.9 (9.0)	0.93	0.007
Weight at first durvalumab (kg), mean (SD)		72.0 (16.5)	75.6 (18.1)	0.009	72.1 (16.8)	73.4 (18.7)	0.43	0.08
BMI (kg/m^2), n (%)	Underweight (<18.5)	17 (6.9%)	22 (4.5%)	0.09	14 (6.3%)	14 (6.2%)	0.78	0.00
	Healthy weight (18.5 to <25)	102 (41.1%)	176 (35.6%)		95 (42.4%)	90 (40.2%)		
	Overweight (25 to <30)	83 (33.5%)	173 (35.0%)		72 (32.1%)	68 (30.4%)		
	Obesity (30+)	46 (18.5%)	123 (24.9%)		43 (19.2%)	52 (23.2%)		
	Missing	0 (0.0%)	NR[§]		0 (0.0%)	0 (0.0%)		

Table S3 *(continued)*

https://dx.doi.org/10.21037/ace-24-16

Table S3 *(continued)*

Baseline characteristics	Category	Original cohort			PSM cohort			Standardized difference
		EXT (N=248)	STD COMB (N=494)	P value	EXT (N=224)	STD COMB (N=224)	P value	
After-tax median household income quintile, n (%)[†]	Highest	44 (17.7%)	84 (17.0%)	0.009	42 (18.8%)	47 (21.0%)	1.00	0.00
	Mid-high	46 (18.5%)	91 (18.4%)		43 (19.2%)	42 (18.7%)		
	Middle	46 (18.5%)	87 (17.6%)		41 (18.3%)	35 (15.6%)		
	Mid-low	62 (25.0%)	105 (21.3%)		55 (24.6%)	55 (24.6%)		
	Lowest	50 (20.3%)	127 (25.7%)		43 (19.2%)	45 (20.1%)		
	Unknown	NR[§]	0 (0.0%)		0 (0.0%)	0 (0.0%)		
Rurality, n (%)[†]	Urban	206 (83.1%)	402 (81.4%)	0.004	189 (84.4%)	186 (83.0%)	0.70	0.00
	Rural	42 (16.9%)	92 (18.6%)		35 (15.6%)	38 (17.0%)		
	Unknown	NR[§]	0 (0.0%)		0 (0.0%)	0 (0.0%)		
Health Region, n (%)[†]	Central	53 (21.4%)	104 (21.1%)	<0.0001	51 (22.2%)	43 (19.2%)	<0.0001	0.00
	East	80 (32.3%)	77 (15.6%)		73 (32.6%)	40 (17.9%)		
	North	NR[§]	73 (14.8%)		NR[§]	36 (16.1%)		
	Toronto	22 (8.9%)	25 (5.1%)		19 (8.5%)	14 (6.2%)		
	West	93 (37.5%)	215 (43.5%)		80 (35.7%)	91 (40.6%)		
Summary Score for the ON-Marginalization Dimensions quintiles[†]	1	50 (20.2%)	104 (21.0%)	0.80	51 (22.9%)	54 (24.1%)	0.98	0.02
	2	48 (19.4%)	89 (18.0%)		44 (19.6%)	46 (20.5%)		
	3	57 (23.0%)	111 (22.5%)		50 (22.3%)	45 (20.1%)		
	4	43 (17.3%)	107 (21.7%)		39 (17.4%)	39 (17.4%)		
	5	43 (17.3%)	83 (16.8%)		40 (17.9%)	40 (17.9%)		
	Missing	7 (2.8%)	NR[§]		NR[§]	NR[§]		
Time from diagnosis to first durvalumab (month), mean (SD)		4.7 (1.3)	5.1 (1.7)	0.001	4.7 (1.2)	4.6 (1.3)	0.33	0.09
Staging group, n (%)	IIIA	82 (33.1%)	180 (36.4%)	0.001	78 (34.8%)	82 (36.6%)	0.74	0.02
	IIIB	75 (30.2%)	178 (36.0%)		66 (29.5%)	67 (29.9%)		
	IIIC	19 (7.7%)	39 (7.9%)		15 (6.7%)	20 (8.9%)		
	III, NOS	20 (8.1%)	49 (9.9%)		16 (7.1%)	16 (7.2%)		
	Unknown/Missing	52 (21.0%)	48 (9.7%)		49 (21.9%)	39 (17.4%)		
ECOG performance status at time of enrolment, n (%)	0	75 (30.2%)	145 (29.3%)	0.94	68 (30.4%)	66 (29.5%)	0.98	0.02
	1	158 (63.7%)	320 (64.8%)		144 (64.3%)	146 (65.2%)		
	2	15 (6.0%)	29 (5.9%)		12 (5.4%)	12 (5.3%)		
	Missing	0 (0.0%)	NR[§]		0 (0.0%)	0 (0.0%)		

Table S3 *(continued)*

https://dx.doi.org/10.21037/ace-24-16

Table S3 *(continued)*

Baseline characteristics	Category	Original cohort			PSM cohort			Standardized difference
		EXT (N=248)	STD COMB (N=494)	P value	EXT (N=224)	STD COMB (N=224)	P value	
Charlson Comorbidity Index, n (%)	0	156 (62.9%)	308 (62.4%)	0.43	142 (63.4%)	146 (65.2%)	0.92	0.02
	1	58 (23.4%)	102 (22.6%)		53 (23.7%)	51 (22.8%)		
	2+	34 (13.7%)	84 (17.0%)		29 (12.9%)	27 (12.0%)		
COPD-specific comorbidity, n (%)	0	218 (87.9%)	418 (84.6%)	0.23	198 (88.4%)	197 (88.0%)	0.88	0.01
	1	30 (12.1%)	76 (15.4%)		26 (11.6%)	27 (12.0%)		
Tumor histologic type, n (%)	Adenocarcinoma	130 (52.4%)	252 (51.0%)	0.68	120 (53.6%)	128 (57.1%)	0.75	0.01
	Squamous cell carcinoma	81 (32.7%)	176 (35.6%)		71 (31.7%)	65 (29.0%)		
	Other	37 (14.9%)	66 (13.4%)		33 (14.7%)	31 (13.9%)		
History of separate prior non-small cell lung cancer, n (%)	Yes	17 (6.9%)	26 (5.3%)	0.38	13 (5.8%)	12 (5.4%)	0.84	0.02
	No	231 (93.1%)	468 (94.7%)		211 (94.2%)	212 (96.6%)		
History of other cancer, n (%)[‡]	Yes	49 (19.8%)	99 (20.0%)	0.93	41 (18.3%)	41 (18.3%)	1.00	0.00
	No	199 (80.2%)	395 (80.0%)		183 (81.7%)	183 (81.7%)		
Previous radiotherapy, n (%)	Yes	231 (93.1%)	453 (91.7%)	0.49	224 (100.0%)	224 (100.0%)	NA	NA
	No	17 (6.9%)	41 (8.3%)		0 (0.0%)	0 (0.0%)		
Time from last rad to first durvalumab (days), mean (SD)		44.0 (22.7)	48.2 (37.9)	0.12	43.4 (22.5)	42.1 (31.3)	0.63	0.05
Last rad to first durvalumab within 6 weeks, n (%)	Yes (≤ 42 d)	134 (58.0%)	274 (60.5%)	0.53	133 (59.4%)	151 (67.4%)	0.08	0.17
	No (> 42 d)	97 (42.0%)	179 (39.5%)		91 (40.6%)	73 (32.6%)		
Total dose of radiation received (Gy), mean (SD)		61.2 (5.2)	60.7 (3.9)	0.12	61.2 (5.2)	61.0 (3.1)	0.49	0.07
Previous chemotherapy, n (%)	Yes	248 (100.0%)	484 (98.0%)	0.21	224 (100.0%)	224 (100.0%)	NA	NA
	No	NR[§]	10 (2.0%)		0 (0.0%)	0 (0.0%)		
Previous chemotherapy platinum type, n (%)	Cisplatin	114 (46.3%)	178 (36.8%)	0.02	104 (46.4%)	105 (46.9%)	0.97	0.00
	Carboplatin	121 (49.2%)	290 (59.9%)		109 (48.7%)	109 (48.7%)		
	Both	11 (4.5%)	16 (3.3%)		11 (4.9%)	10 (4.4%)		
Time from last chemotherapy to first durvalumab (days), mean (SD)		53.6 (23.7)	57.3 (38.8)	0.16	52.9 (23.5)	51.1 (31.4)	0.48	0.07
Last chemo to first durvalumab within 6 weeks, n (%)	Yes (≤ 42 d)	87 (35.4%)	182 (37.6%)	0.55	79 (35.3%)	87 (38.8%)	0.43	0.07
	No (> 42 d)	159 (64.6%)	302 (62.4%)		145 (64.7%)	137 (61.2%)		
Previous chemoradiation, n (%)	Yes	229 (92.3%)	446 (90.3%)	0.36	224 (100.0%)	224 (100.0%)	NA	NA
	No	19 (7.7%)	48 (9.7%)		0 (0.0%)	0 (0.0%)		

[†] source (or adapted from): Statistics Canada Postal Code Conversion File and Postal Code Conversion File Plus (version 7D, received April 2021) which is based on data licensed from Canada Post Corporation. The patients' postal code at first durvalumab treatment was used. [‡] Other cancer including non-lung cancer and small cell lung cancer. [§] Cells with <6 were not reported (NR). To prevent back-calculation, numbers were combined with underweight, lowest household income, rural residence, Central, ON-Marg quintile 1, ECOG status 0, and previous chemotherapy yes.

https://dx.doi.org/10.21037/ace-24-16

Table S4 Durvalumab treatment characteristics for combined switching group and extended dosing group

Treatment Characteristics	Original cohort			PSM cohort			Standardized difference
	EXT (N=248)	STD COMB (N=494)	P value	EXT (N=224)	STD COMB (N=224)	P value	
Total number of treatments, mean (SD)	9.0 (4.1)	17.2 (8.2)	<0.0001	9.0 (4.1)	17.4 (8.3)	<0.0001	1.27
Total dose of Durvalumab received (mg), mean (SD)	12002.0 (5878.0)	13906.9 (7322.7)	<0.0001	12101.6 (5840.5)	13663.5 (7193.3)	0.012	0.24
Avg dose per visit (mg), mean (SD)	1342.7 (196.4)	822.7 (228.3)	<0.0001	1343.0 (196.9)	807.7 (233.4)	<0.0001	2.48
Treatment duration (month) - from first dose to the end of last cycle, mean (SD)	8.9 (4.0)	9.4 (4.1)	0.13	8.9 (4.0)	9.3 (4.1)	0.30	0.10
Prior approval submitted for extended dosing interval modification, n (%)							
Yes	144 (58.1%)	97 (19.6%)	<0.0001	128 (57.1%)	43 (19.2%)	<0.0001	0.85
No	104 (41.9%)	397 (80.4%)		96 (42.9%)	181 (80.8%)		
Treatment started after policy measures effective date (April 9, 2020), n (%)							
No (before April 9, 2020)	0 (0.0%)	223 (45.1%)	NA	0 (0.0%)	128 (57.1%)	NA	NA
Yes (on/after April 9, 2020)	248 (100.0%)	271 (54.9%)		224 (100.0%)	96 (42.9%)		
Treatment started in COVID period by wave, n (%)							
Pre-COVID (Jan 22, 2020 to Mar 10, 2020)	0 (0.0%)	193 (39.1%)	<0.0001	0 (0.0%)	83 (37.1%)	<0.0001	1.22
Wave 1, wildtype (Mar 11, 2020 to Jul 17, 2020)	42 (16.9%)	89 (18.0%)		38 (17.0%)	45 (20.1%)		
Wave 2, wildtype (Jul 18, 2020 to Mar 04, 2021)	82 (33.1%)	90 (18.2%)		73 (32.6%)	45 (20.1%)		
Wave 3, Alpha (Mar 05, 2021 to Jul 22, 2021)	62 (25.0%)	65 (13.2%)		58 (25.9%)	28 (12.5%)		
Wave 4, Delta (Jul 23, 2021 to Nov 03, 2021)	43 (17.3%)	42 (8.5%)		39 (17.4%)	23 (10.2%)		
Wave 5, Omicron (Nov 04, 2021 to Dec 31, 2021)	19 (7.7%)	15 (3.0%)		16 (7.1%)	NR[†]		

[†] Cell with <6 was not reported (NR). To prevent back-calculation, numbers were combined with COVID period wave 4.

https://dx.doi.org/10.21037/ace-24-16

Table S5 Overall survival for original and PSM cohorts for combined switching group and extended dosing group

Cohort	Model	Hazard ratio (95% CI)	P value	P value (Proportionality test)
Original cohort	Crude Cox Proportional Model[†]	0.99 (0.74, 1.33)	0.95	0.25
	Adjusted Cox Proportional Model 1[‡]	0.96 (0.69, 1.34)	0.81	0.64
	Adjusted Cox Proportional Model 2[§]	0.96 (0.68, 1.37)	0.83	0.94
PSM cohort	Matched Cox Proportional Model[‡]	1.03 (0.71, 1.49)	0.87	0.69
	Matched Cox Proportional Model adjusted for health region	1.05 (0.71, 1.55)	0.80	0.93

[†] Crude Cox Proportional Model evaluates the direct impact of the primary exposure variable (dosing interval) on overall survival without adjusting for any covariates. [‡] Adjusted for/Matched on age, sex, weight, BMI group, income, rurality, ON-Marginalization, Charlson comorbidity index, COPD-specific comorbidity, ECOG status, staging, tumor histologic type, previous NSCLC diagnosis, previous non-NSCLC diagnosis, time from diagnosis to the first durvalumab, time from the last radiotherapy to the first durvalumab, sum dose of previous radiotherapy, time from the last chemotherapy to the first durvalumab, and previous chemotherapy type. [§] Adjusted for all covariates in Adjusted Cox Proportional Model 1 plus health region.

Table S6 Unscheduled emergency department visits during durvalumab treatment for original and PSM cohorts for combined switching group and extended dosing group

Cohort	Dosing	Crude event rate per 100 person-months (95% CI)	Model	RR (95% CI)	P value
Original cohort	EXT	4.9 (3.3, 7.2)	Crude Model	1.52 (0.94, 2.44)	0.09
	STD COMB	3.2 (2.4, 4.3)	Adjusted Model[†]	1.65 (0.97, 2.79)	0.07
PSM cohort	EXT	5.1 (3.3, 8.0)	Matched Model[‡]	1.26 (0.67, 2.37)	0.48
	STD COMB	4.1 (2.6, 6.3)	Adjusted Model[†]	1.52 (0.75, 3.10)	0.24

[†] Adjusted for health region. [‡] Matched on age, sex, weight, BMI group, income, rurality, ON-Marginalization, Charlson comorbidity index, COPD-specific comorbidity, ECOG status, staging, tumor histologic type, previous NSCLC diagnosis, previous non-NSCLC diagnosis, time from diagnosis to the first durvalumab, time from the last radiotherapy to the first durvalumab, sum dose of previous radiotherapy, time from the last chemotherapy to the first durvalumab, and previous chemotherapy type.

Table S7 Hospital encounters during durvalumab treatment for original and PSM cohorts for combined switching group and extended dosing group

Cohort	Dosing	Crude event rate per 100 person-months (95% CI)	Model	RR (95% CI)	P value
Original cohort	EXT	2.5 (0.9, 6.9)	Crude Model	0.67 (0.24, 1.95)	0.47
	STD COMB	2.1 (1.0, 4.4)	Adjusted Model[†]	0.52 (0.23, 1.19)	0.12
PSM cohort	EXT	2.3 (0.8, 6.3)	Matched Model[‡]	0.59 (0.14, 2.58)	0.49
	STD COMB	3.8 (1.4, 10.3)	Adjusted Model[†]	0.37 (0.10, 1.34)	0.13

[†] Adjusted for health region. [‡] Matched on age, sex, weight, BMI group, income, rurality, ON-Marginalization, Charlson comorbidity index, COPD-specific comorbidity, ECOG status, staging, tumor histologic type, previous NSCLC diagnosis, previous non-NSCLC diagnosis, time from diagnosis to the first durvalumab, time from the last radiotherapy to the first durvalumab, sum dose of previous radiotherapy, time from the last chemotherapy to the first durvalumab, and previous chemotherapy type.

https://dx.doi.org/10.21037/ace-24-16

Table S8 Baseline characteristics for combined switching group and standard dosing group

Baseline characteristics	Category	Original cohort			PSM cohort			Standardized difference
		EXT COMB (N=348)	STD (N=394)	P value	EXT COMB (N=316)	STD (N=316)	P value	
Age at first durvalumab (yrs), mean (SD)		66.9 (8.5)	67.8 (7.9)	0.13	67.3 (8.0)	67.7 (7.7)	0.54	0.05
Sex, n (%)	Female	157 (45.1%)	173 (43.9%)	0.74	138 (43.7%)	138 (43.7%)	1.00	0.00
	Male	191 (54.9%)	221 (56.1%)		178 (56.3%)	178 (56.3%)		
Height (cm), mean (SD)		166.9 (9.2)	167.3 (9.1)	0.55	167.1 (9.1)	167.3 (9.1)	0.89	0.03
Weight at first durvalumab (kg), mean (SD)		72.7 (16.5)	75.9 (18.5)	0.014	73.0 (16.7)	75.0 (17.9)	0.14	0.12
BMI (kg/m^2), n (%)	Underweight (<18.5)	19 (5.4%)	20 (5.1%)	0.07	16 (5.1%)	14 (4.4%)	0.32	0.03
	Healthy weight (18.5 to <25)	144 (41.4%)	134 (34.0%)		133 (42.1%)	113 (35.8%)		
	Overweight (25 to <30)	119 (34.2%)	137 (34.8%)		105 (33.2%)	113 (35.8%)		
	Obesity (30+)	66 (19.0%)	103 (26.1%)		62 (19.6%)	76 (24.1%)		
	Missing	0 (0.0%)	NR[§]		0 (0.0%)	0 (0.0%)		
After-tax median household income quintile, n (%)[†]	Highest	64 (18.4%)	64 (16.2%)	0.09	61 (19.3%)	53 (16.8%)	0.73	0.03
	Mid-high	66 (19.0%)	71 (18.0%)		62 (19.6%)	59 (18.7%)		
	Middle	63 (18.1%)	70 (17.8%)		57 (18.0%)	56 (17.7%)		
	Mid-low	81 (23.3%)	86 (21.8%)		70 (22.2%)	68 (21.5%)		
	Lowest	74 (21.2%)	103 (26.1%)		66 (20.9%)	80 (25.3%)		
	Unknown	NR[§]	0 (0.0%)		0 (0.0%)	0 (0.0%)		
Rurality, n (%)[†]	Urban	292 (83.9%)	316 (80.2%)	0.012	268 (84.8%)	258 (81.7%)	0.29	0.03
	Rural	56 (16.1%)	78 (19.8%)		48 (15.2%)	58 (18.4%)		
	Unknown	NR[§]	0 (0.0%)		0 (0.0%)	0 (0.0%)		
Health Region, n (%)[†]	Central	80 (23.0%)	77 (19.5%)	<0.0001	78 (24.7%)	51 (16.1%)	<0.0001	0.03
	East	114 (32.7%)	43 (10.9%)		104 (32.9%)	36 (11.4%)		
	North	NR[§]	73 (18.5%)		NR[§]	64 (20.3%)		
	Toronto	33 (9.5%)	14 (3.6%)		27 (8.5%)	12 (3.8%)		
	West	121 (34.8%)	187 (47.5%)		107 (33.9%)	153 (48.4%)		
Summary Score for the ON-Marginalization Dimensions quintiles[†]	1	75 (21.6%)	79 (20.0%)	0.70	75 (23.7%)	63 (20.0%)	0.78	0.02
	2	64 (18.4%)	73 (18.5%)		59 (18.7%)	61 (19.3%)		
	3	80 (23.0%)	88 (22.3%)		69 (21.8%)	72 (22.8%)		
	4	64 (18.4%)	86 (21.8%)		59 (18.7%)	63 (19.9%)		
	5	58 (16.6%)	68 (17.3%)		54 (17.1%)	57 (18.0%)		
	Missing	7 (2.0%)	NR[§]		NR[§]	NR[§]		
Time from diagnosis to first durvalumab (month), mean (SD)		4.8 (1.5)	5.1 (1.6)	0.07	4.8 (1.4)	5.0 (1.5)	0.15	0.11

Table S8 *(continued)*

https://dx.doi.org/10.21037/ace-24-16

Table S8 *(continued)*

Baseline characteristics	Category	Original cohort			PSM cohort			Standardized difference
		EXT COMB (N=348)	STD (N=394)	P value	EXT COMB (N=316)	STD (N=316)	P value	
Staging group, n (%)	IIIA	119 (34.2%)	143 (36.3%)	0.003	113 (35.8%)	116 (36.7%)	0.012	0.02
	IIIB	107 (30.8%)	146 (37.1%)		98 (31.0%)	118 (37.3%)		
	IIIC	24 (6.9%)	34 (8.6%)		20 (6.3%)	26 (8.2%)		
	III, NOS	33 (9.5%)	36 (9.1%)		26 (8.2%)	27 (8.6%)		
	Unknown/Missing	65 (18.7%)	35 (8.9%)		59 (18.7%)	29 (9.2%)		
ECOG performance status at time of enrolment, n (%)	0	112 (32.2%)	108 (27.4%)	0.31	103 (32.6%)	89 (28.2%)	0.46	0.02
	1	216 (62.1%)	262 (66.5%)		196 (62.0%)	207 (65.5%)		
	2	20 (5.7%)	24 (6.1%)		17 (5.4%)	20 (6.3%)		
	Missing	0 (0.0%)	NR[§]		0 (0.0%)	0 (0.0%)		
Charlson Comorbidity Index, n (%)	0	234 (67.2%)	230 (58.4%)	0.02	215 (68.0%)	195 (61.7%)	0.18	0.02
	1	71 (20.4%)	89 (22.6%)		64 (20.3%)	70 (22.2%)		
	2+	43 (12.4%)	75 (19.0%)		37 (11.7%)	51 (16.1%)		
COPD-specific comorbidity, n (%)	0	309 (88.8%)	327 (83.0%)	0.02	283 (89.6%)	271 (85.8%)	0.15	0.12
	1	39 (11.2%)	67 (17.0%)		33 (10.4%)	45 (14.2%)		
Tumor histologic type, n (%)	Adenocarcinoma	187 (53.7%)	195 (49.5%)	0.20	172 (54.4%)	165 (52.2%)	0.26	0.12
	Squamous cell carcinoma	109 (31.3%)	148 (37.6%)		97 (30.7%)	114 (36.1%)		
	Other	52 (15.0%)	51 (12.9%)		47 (14.9%)	37 (11.7%)		
History of separate prior non-small cell lung cancer, n (%)	Yes	24 (6.9%)	19 (4.8%)	0.23	19 (6.0%)	13 (4.1%)	0.28	0.09
	No	324 (93.1%)	375 (95.2%)		297 (94.0%)	303 (95.9%)		
History of other cancer, n (%)[‡]	Yes	71 (20.4%)	77 (19.5%)	0.77	62 (19.6%)	64 (20.3%)	0.84	0.02
	No	277 (79.6%)	317 (80.5%)		254 (80.4%)	252 (79.7%)		
Previous radiotherapy, n (%)	Yes	327 (94.0%)	357 (90.6%)	0.09	316 (100.0%)	316 (100.0%)	NA	NA
	No	21 (6.0%)	37 (9.4%)		0 (0.0%)	0 (0.0%)		
Time from last rad to first durvalumab (day), mean (SD)		46.2 (31.6)	47.3 (35.4)	0.66	45.9 (31.9)	45.5 (34.0)	0.85	0.01
Last rad to first durvalumab within 6 weeks, n (%)	Yes (≤42 d)	196 (59.9%)	212 (59.4%)	0.88	191 (60.4%)	197 (62.3%)	0.62	0.04
	No (>42 d)	131 (40.1%)	145 (40.6%)		125 (39.6%)	119 (37.7%)		
Total dose of radiation received (Gy), mean (SD)		61.2 (5.0)	60.5 (3.7)	0.02	61.3 (5.0)	60.6 (3.5)	0.05	0.16
Previous chemotherapy, n (%)	Yes	348 (100.0%)	385 (97.7%)	0.13	316 (100.0%)	316 (100.0%)	NA	NA
	No	NR[§]	9 (2.3%)		0 (0.0%)	0 (0.0%)		

Table S8 *(continued)*

https://dx.doi.org/10.21037/ace-24-16

Table S8 *(continued)*

Baseline characteristics	Category	Original cohort			PSM cohort			Standardized difference
		EXT COMB (N=348)	STD (N=394)	P value	EXT COMB (N=316)	STD (N=316)	P value	
Previous chemotherapy platinum type, n (%)	Cisplatin	156 (45.2%)	136 (35.3%)	0.001	144 (45.6%)	116 (36.7%)	0.006	0.04
	Carboplatin	171 (49.6%)	240 (62.3%)		155 (49.0%)	192 (60.8%)		
	Both	18 (5.2%)	9 (2.3%)		17 (5.4%)	8 (2.5%)		
Time from last chemotherapy to first durvalumab (days), mean (SD)		55.3 (31.7)	56.7 (36.9)	0.59	55.4 (32.2)	54.2 (34.6)	0.66	0.03
Last chemo to first durvalumab within 6 weeks, n (%)	Yes (≤42 d)	126 (36.5%)	143 (37.1%)	0.86	113 (35.8%)	124 (39.2%)	0.37	0.07
	No (>42 d)	219 (63.5%)	242 (62.9%)		203 (64.2%)	192 (60.8%)		
Previous chemoradiation, n (%)	Yes	325 (93.4%)	350 (88.8%)	0.03	316 (100.0%)	316 (100.0%)	NA	NA
	No	23 (6.6%)	44 (11.2%)		0 (0.0%)	0 (0.0%)		

[†] source (or adapted from): Statistics Canada Postal Code Conversion File and Postal Code Conversion File Plus (version 7D, received April 2021) which is based on data licensed from Canada Post Corporation. The patients' postal code at first durvalumab treatment was used. [‡] Other cancer including non-lung cancer and small cell lung cancer. [§] Cells with <6 were not reported (NR). To prevent back-calculation, numbers were combined with underweight, lowest household income, rural residence, Central, ON-Marg quintile 1, ECOG status 0, and previous chemotherapy yes.

https://dx.doi.org/10.21037/ace-24-16

Table S9 Durvalumab treatment characteristics for combined switching group and standard dosing group

Treatment Characteristics	Original cohort			PSM cohort			Standardized difference
	EXT COMB (N=348)	STD (N=394)	P value	EXT COMB (N=316)	STD (N=316)	P value	
Total number of treatments, mean (SD)	10.4 (5.1)	18.0 (8.6)	<0.0001	10.6 (5.1)	17.9 (8.5)	<0.0001	1.05
Total dose of Durvalumab received (mg), mean (SD)	12715.6 (5899.8)	13760.0 (7698.0)	0.04	12886.1 (5898.6)	13485.8 (7439.1)	0.26	0.09
Avg dose per visit (mg), mean (SD)	1262.2 (239.0)	761.8 (187.2)	<0.0001	1259.9 (240.5)	753.4 (181.4)	<0.0001	2.38
Treatment duration (month) - from first dose to the end of last cycle, mean (SD)	9.3 (3.9)	9.1 (4.2)	0.54	9.3 (3.9)	9.0 (4.3)	0.41	0.07
Prior approval submitted for extended dosing interval modification, n (%)							
Yes	237 (68.1%)	NR[†]	<0.0001	213 (67.4%)	NR[†]	<0.0001	1.96
No	111 (31.9%)	394 (100.0%)		103 (32.6%)	316 (100.0%)		
Treatment started after policy measures effective date (April 9, 2020), n (%)							
No (before April 9, 2020)	70 (20.1%)	153 (38.8%)	<0.001	67 (21.2%)	122 (38.6%)	<0.001	0.39
Yes (on/after April 9, 2020)	278 (79.9%)	241 (61.2%)		249 (78.8%)	194 (61.4%)		
Treatment started in COVID period by wave, n (%)							
Pre-COVID (Jan 22, 2020 to Mar 10, 2020)	55 (15.8%)	138 (35.0%)	<0.001	53 (16.8%)	110 (34.8%)	<0.001	0.39
Wave 1, wildtype (Mar 11, 2020 to Jul 17, 2020)	73 (21.0%)	58 (14.7%)		66 (20.9%)	51 (16.2%)		
Wave 2, wildtype (Jul 18, 2020 to Mar 04, 2021)	88 (25.3%)	84 (21.3%)		77 (24.3%)	67 (21.2%)		
Wave 3, Alpha (Mar 05, 2021 to Jul 22, 2021)	65 (18.7%)	62 (15.7%)		61 (19.3%)	48 (15.2%)		
Wave 4, Delta (Jul 23, 2021 to Nov 03, 2021)	47 (13.5%)	38 (9.6%)		42 (13.3%)	27 (8.5%)		
Wave 5, Omicron (Nov 04, 2021 to Dec 31, 2021)	20 (5.7%)	14 (3.6%)		17 (5.4%)	13 (4.1%)		

[†] Cells with <6 were not reported (NR). To prevent back-calculation, numbers were combined with no prior approval submitted for extended dosing interval modification.

https://dx.doi.org/10.21037/ace-24-16

Table S10 Overall survival for original and PSM cohorts for combined switching group and standard dosing group

Cohort	Model	Hazard ratio (95% CI)	P value	P value (Proportionality test)
Original cohort	Crude Cox Proportional Model[†]	0.89 (0.68, 1.17)	0.40	0.73
	Adjusted Cox Proportional Model 1[‡]	0.93 (0.68, 1.26)	0.63	0.96
	Adjusted Cox Proportional Model 2[§]	0.97 (0.70, 1.35)	0.85	0.92
PSM cohort	Matched Cox Proportional Model[‡]	1.18 (0.88, 1.59)	0.28	1.00
	Matched Cox Proportional Model adjusted for health region	1.11 (0.80, 1.53)	0.53	0.99

[†]Crude Cox Proportional Model evaluates the direct impact of the primary exposure variable (dosing interval) on overall survival without adjusting for any covariates. [‡] Adjusted for/Matched on age, sex, weight, BMI group, income, rurality, ON-Marginalization, Charlson comorbidity index, COPD-specific comorbidity, ECOG status, staging, tumor histologic type, previous NSCLC diagnosis, previous non-NSCLC diagnosis, time from diagnosis to the first durvalumab, time from the last radiotherapy to the first durvalumab, sum dose of previous radiotherapy, time from the last chemotherapy to the first durvalumab, and previous chemotherapy type. [§] Adjusted for all covariates in Adjusted Cox Proportional Model 1 plus health region.

Table S11 Unscheduled emergency department visits during durvalumab treatment for original and PSM cohorts for combined switching group and standard dosing group

Cohort	Dosing	Crude event rate per 100 person-months (95% CI)	Model	RR (95% CI)	P value
Original cohort	EXT COMB	4.0 (2.9, 5.6)	Crude Model	1.13 (0.71, 1.78)	0.60
	STD	3.6 (2.6, 4.9)	Adjusted Model[†]	1.36 (0.64, 2.93)	0.42
PSM cohort	EXT COMB	3.9 (3.0, 5.1)	Matched Model[‡]	1.57 (0.74, 3.30)	0.24
	STD	4.1 (2.8, 5.9)	Adjusted Model[†]	2.00 (0.87, 4.58)	0.10

[†] Adjusted for health region. [‡] Matched on age, sex, weight, BMI group, income, rurality, ON-Marginalization, Charlson comorbidity index, COPD-specific comorbidity, ECOG status, staging, tumor histologic type, previous NSCLC diagnosis, previous non-NSCLC diagnosis, time from diagnosis to the first durvalumab, time from the last radiotherapy to the first durvalumab, sum dose of previous radiotherapy, time from the last chemotherapy to the first durvalumab, and previous chemotherapy type.

Table S12 Hospital encounters during durvalumab treatment for original and PSM cohorts for combined switching group and extended dosing group

Cohort	Dosing	Crude event rate per 100 person-months (95% CI)	Model	RR (95% CI)	P value
Original cohort	EXT COMB	2.0 (0.8, 4.8)	Crude Model	0.56 (0.20, 1.58)	0.28
	STD	2.4 (1.1, 5.5)	Adjusted Model[†]	0.59 (0.29, 1.19)	0.14
PSM cohort	EXT COMB	1.9 (0.7, 4.9)	Matched Model[‡]	0.53 (0.15, 1.82)	0.31
	STD	2.3 (1.2, 4.5)	Adjusted Model[†]	0.55 (0.22, 1.37)	0.20

[†] Adjusted for health region. [‡] Matched on age, sex, weight, BMI group, income, rurality, ON-Marginalization, Charlson comorbidity index, COPD-specific comorbidity, ECOG status, staging, tumor histologic type, previous NSCLC diagnosis, previous non-NSCLC diagnosis, time from diagnosis to the first durvalumab, time from the last radiotherapy to the first durvalumab, sum dose of previous radiotherapy, time from the last chemotherapy to the first durvalumab, and previous chemotherapy type.

https://dx.doi.org/10.21037/ace-24-16



Figure S1 Kaplan-Meier plots for overall survival (Kaplan-Meier plots for overall survival by treatment group for combined switching group and extended dosing group). (A) For the original cohort. (B) For the PSM cohort. EXT, extended dosing; PSM, propensity score matched; STD COMB, standard dosing combined with STD to EXT.



Figure S2 Kaplan-Meier plots for overall survival (Kaplan-Meier plots for overall survival by treatment group for combined switching group and standard dosing group). (A) For the original cohort. (B) For the PSM cohort. EXT COMB, extended dosing combined with STD to EXT; PSM, propensity score matched; STD, standard dosing.

https://dx.doi.org/10.21037/ace-24-16

Table S13 Baseline characteristics for switching and non-switching groups

Baseline Characteristics	Category	EXT (N=248)	STD (N=394)	STD to EXT (N=100)	STD to EXT to STD (N=12)	TOTAL[†] (N=754)	P value
Age at first durvalumab (yrs), mean (SD)		67.4 (8.2)	67.8 (7.9)	65.7 (9.0)	62.6 (10.5)	67.3 (8.2)	0.02
Sex, n (%)	Female	112 (45.2%)	173 (43.9%)	45 (45.0%)	NR[¶]	333 (44.2%)	0.62
	Male	136 (54.8%)	221 (56.1%)	55 (55.0%)	12 (100.0%)	421 (55.8%)	
Height (cm), mean (SD)		166.9 (9.3)	167.3 (9.1)	167 (8.8)	170.2 (10.5)	167.2 (9.2)	0.64
Weight at first durvalumab (kg), mean (SD)		72 (16.5)	75.9 (18.5)	74.4 (16.3)	83.8 (27.6)	74.5 (17.9)	0.02
BMI (kg/m^2), n (%)	Underweight (<18.5)	17 (6.9%)	19 (4.8%)	NR[¶]	NR[¶]	39 (5.2%)	0.10
	Healthy weight (18.5 to <25)	102 (41.1%)	134 (34.0%)	42 (42.0%)	NR[¶]	279 (37.0%)	
	Overweight (25 to <30)	83 (33.5%)	137 (34.8%)	38 (38.0%)	6 (50.0%)	262 (34.7%)	
	Obesity (30+)	46 (18.5%)	106 (26.4%)	20 (20.0%)	6 (50.0%)	174 (23.1%)	
	Missing	0 (0.0%)	NR[¶]	0 (0.0%)	0 (0.0%)	NR[¶]	
After-tax median household income quintile, n (%)[‡]	Highest	44 (17.7%)	64 (16.2%)	20 (20.0%)	NR[¶]	132 (17.5%)	0.11
	Mid-high	46 (18.5%)	71 (18.0%)	20 (20.0%)	0 (0.0%)	137 (18.2%)	
	Middle	46 (18.5%)	70 (17.8%)	17 (17.0%)	NR[¶]	134 (17.8%)	
	Mid-low	62 (25.0%)	86 (21.8%)	19 (19.0%)	NR[¶]	170 (22.5%)	
	Lowest	47 (20.3%)	103 (26.1%)	24 (24.0%)	12 (100.0%)	181 (24.0%)	
	Unknown	NR[¶]	0 (0.0%)	0 (0.0%)	0 (0.0%)	NR[¶]	
Rurality, n (%)[‡]	Urban	211 (85.1%)	316 (80.2%)	86 (86.0%)	12 (100.0%)	623 (82.6%)	0.05
	Rural	37 (14.9%)	78 (19.8%)	14 (14.0%)	NR[¶]	131 (17.4%)	
	Unknown	NR[¶]	0 (0.0%)	0 (0.0%)	0 (0.0%)	NR[¶]	
Health Region, n (%)[‡]	Central	52 (21.0%)	77 (19.5%)	27 (27.0%)	0 (0.0%)	156 (20.7%)	<0.0001
	East	81 (32.6%)	43 (10.9%)	34 (34.0%)	12 (100.0%)	162 (21.5%)	
	North	NR[¶]	73 (18.5%)	0 (0.0%)	0 (0.0%)	74 (9.8%)	
	Toronto	22 (8.9%)	14 (3.6%)	11 (11.0%)	NR[¶]	49 (6.5%)	
	West	93 (37.5%)	187 (47.5%)	28 (28.0%)	NR[¶]	313 (41.5%)	
Summary Score for the ON-Marginalization Dimensions quintiles[‡]	1	50 (20.2%)	79 (20.1%)	25 (25.0%)	12 (100.0%)	153 (20.3%)	0.68
	2	48 (19.4%)	73 (18.5%)	16 (16.0%)	NR[¶]	139 (18.4%)	
	3	57 (23.0%)	88 (22.3%)	23 (23.0%)	NR[¶]	170 (22.5%)	
	4	43 (17.3%)	86 (21.8%)	21 (21.0%)	NR[¶]	151 (20.0%)	
	5	43 (17.3%)	68 (17.3%)	15 (15.0%)	NR[¶]	130 (17.2%)	
	Missing	7 (2.8%)	NR[¶]	0 (0.0%)	0 (0.0%)	11 (1.5%)	
Time from diagnosis to first durvalumab (month), mean (SD)		4.7 (1.3)	5.1 (1.6)	5.1 (2.0)	5.5 (2.1)	5 (1.6)	0.009

Table S13 *(continued)*

https://dx.doi.org/10.21037/ace-24-16

Table S13 *(continued)*

Baseline Characteristics	Category	EXT (N=248)	STD (N=394)	STD to EXT (N=100)	STD to EXT to STD (N=12)	TOTAL[†] (N=754)	P value
Staging group, n (%)	IIIA	82 (33.1%)	143 (36.3%)	42 (42.0%)	12 (100.0%)	270 (35.8%)	0.005
	IIIB	75 (30.2%)	146 (37.1%)	32 (32.0%)	NR[¶]	255 (33.8%)	
	IIIC	19 (7.7%)	34 (8.6%)	NR[¶]	NR[¶]	59 (7.8%)	
	III, NOS	20 (8.1%)	36 (9.1%)	13 (13.0%)	0 (0.0%)	69 (9.2%)	
	Unknown/Missing	52 (21.0%)	35 (8.9%)	13 (13.0%)	NR[¶]	101 (13.4%)	
ECOG performance status at time of enrolment, n (%)	0	75 (30.2%)	108 (27.4%)	42 (42.0%)	12 (100.0%)	227 (30.1%)	0.17
	1	158 (63.7%)	262 (66.5%)	58 (58.0%)	NR[¶]	482 (63.9%)	
	2	15 (6.0%)	24 (6.1%)	NR[¶]	NR[¶]	45 (6.0%)	
	Missing	0 (0.0%)	NR[¶]	0 (0.0%)	0 (0.0%)	NR[¶]	
Charlson Comorbidity Index, n (%)	0	156 (62.9%)	230 (58.4%)	78 (78.0%)	12 (100.0%)	473 (62.7%)	0.012
	1	58 (23.4%)	89 (22.6%)	13 (13.0%)	NR[¶]	161 (21.4%)	
	2+	34 (13.7%)	75 (19.0%)	9 (9.0%)	NR[¶]	120 (15.9%)	
COPD-specific comorbidity, n (%)	0	218 (87.9%)	327 (83.0%)	91 (91.0%)	12 (100.0%)	647 (85.8%)	0.12
	1	30 (12.1%)	67 (17.0%)	9 (9.0%)	NR[¶]	107 (14.2%)	
Tumor histologic type, n (%)	Adenocarcinoma	130 (52.4%)	195 (49.5%)	57 (57.0%)	12 (100.0%)	387 (51.3%)	0.62
	Squamous cell carcinoma	81 (32.7%)	148 (37.6%)	28 (28.0%)	NR[¶]	262 (34.7%)	
	Other	37 (14.9%)	51 (12.9%)	15 (15.0%)	NR[¶]	105 (13.9%)	
History of non-small cell lung cancer, n (%)	Yes	17 (6.9%)	19 (4.8%)	7 (7.0%)	0 (0.0%)	43 (5.7%)	0.57
	No	231 (93.1%)	375 (95.2%)	93 (93.0%)	12 (100.0%)	711 (94.3%)	
History of other cancer, n (%)[§]	Yes	49 (19.8%)	77 (19.5%)	22 (22.0%)	NR[¶]	150 (19.9%)	0.95
	No	199 (80.2%)	317 (80.5%)	78 (78.0%)	12 (100.0%)	604 (80.1%)	
Previous radiotherapy, n (%)	Yes	231 (93.1%)	357 (90.6%)	100 (100.0%)	12 (100.0%)	696 (92.3%)	0.25
	No	17 (6.9%)	37 (9.4%)	NR[¶]	0 (0.0%)	58 (7.7%)	
Time from last rad to first durvalumab (day), mean (SD)		44 (22.7)	47.3 (35.4)	51.4 (46.3)	57.1 (59.3)	46.9 (34.2)	0.21
Last rad to first durvalumab within 6 weeks, n (%)	Yes (≤42 d)	134 (58.0%)	212 (59.4%)	62 (64.6%)	12 (100.0%)	416 (59.8%)	0.70
	No (>42 d)	97 (42.0%)	145 (40.6%)	34 (35.4%)	NR[¶]	280 (40.2%)	
Total dose of radiation received (Gy), mean (SD)		61.2 (5.2)	60.5 (3.7)	61.3 (4.5)	62.8 (4.7)	60.9 (4.4)	0.06
Previous chemotherapy, n (%)	Yes	248 (100.0%)	385 (97.7%)	100 (100.0%)	12 (100.0%)	742 (98.4%)	0.47
	No	NR[¶]	9 (2.3%)	NR[¶]	0 (0.0%)	12 (1.6%)	
Previous chemotherapy platinum type, n (%)	Cisplatin	114 (46.3%)	136 (35.3%)	42 (42.4%)	NR[¶]	297 (40.0%)	0.014
	Carboplatin	121 (49.2%)	240 (62.3%)	50 (50.5%)	12 (100.0%)	418 (56.3%)	
	Both	11 (4.5%)	9 (2.3%)	7 (7.1%)	0 (0.0%)	27 (3.6%)	

Table S13 *(continued)*

https://dx.doi.org/10.21037/ace-24-16

Table S13 *(continued)*

Baseline Characteristics	Category	EXT (N=248)	STD (N=394)	STD to EXT (N=100)	STD to EXT to STD (N=12)	TOTAL[†] (N=754)	P value
Time from last chemotherapy to first durvalumab (days), mean (SD)		53.6 (23.7)	56.7 (36.9)	59.7 (45.6)	75.4 (59.4)	56.4 (35)	0.11
Last chemo to first durvalumab within 6 weeks, n (%)	Yes (≤42 d)	87 (35.4%)	143 (37.1%)	39 (39.4%)	NR[¶]	273 (36.8%)	0.91
	No (>42 d)	159 (64.6%)	242 (62.9%)	60 (60.6%)	12 (100.0%)	469 (63.2%)	
Previous chemoradiation, n (%)	Yes	229 (92.3%)	350 (88.8%)	100 (100.0%)	12 (100.0%)	687 (91.1%)	0.08
	No	19 (7.7%)	44 (11.2%)	NR[¶]	0 (0.0%)	67 (8.9%)	

[†] Excluding 3 switching groups (n=17) due to small numbers: EXT to STD, EXT to STD to EXT, and STD to EXT to STD to EXT. [‡] source (or adapted from): Statistics Canada Postal Code Conversion File and Postal Code Conversion File Plus (version 7D, received April 2021) which is based on data licensed from Canada Post Corporation. The patients' postal code at first durvalumab treatment was used. [§] Other cancer including non-lung cancer and small cell lung cancer. [¶] Cells with <6 were not reported (NR). To prevent back-calculation, numbers were combined with male, obesity, lowest household income, urban residence, East, ON-Marg quintile 1, staging IIIA, ECOG status 0, Charlson Comorbidity Index 0, COPD-specific comorbidity 0, adenocarcinoma, no history of other cancer, previous radiotherapy yes, last rad to first durvalumab within 6 weeks, previous chemotherapy yes, carboplatin, last chemo to first durvalumab over 6 weeks and previous chemoradiation yes.

https://dx.doi.org/10.21037/ace-24-16

Table S14 Durvalumab treatment characteristics for switching and non-switching groups

Treatment Characteristics	EXT (N=248)	STD (N=394)	STD to EXT (N=100)	STD to EXT to STD (N=12)	TOTAL[†] (N=754)	P value
Total number of treatments, mean (SD)	9 (4.1)	18 (8.6)	14 (5.5)	17.3 (4.7)	14.5 (8.1)	<0.0001
Total dose of Durvalumab received (mg), mean (SD)	12002.0 (5878.0)	13760.0 (7698.0)	14485.4 (5599.9)	18869.8 (6473.3)	13359.3 (6952.7)	<0.0001
Avg dose per visit (mg), mean (SD)	1342.7 (196.4)	761.8 (187.2)	1062.6 (217.9)	1099.8 (264.7)	998.1 (327.5)	<0.0001
Treatment duration (month) - from first dose to the end of last cycle, mean (SD)	8.9 (4.0)	9.1 (4.2)	10.3 (3.4)	12.4 (1.8)	9.2 (4.1)	<0.001
Prior approval submitted for extended dosing interval modification, n (%)						
Yes	144 (58.1%)	NR[‡]	93 (93.0%)	12 (100.0%)	251 (33.3%)	<0.0001
No	104 (41.9%)	394 (100.0%)	7 (7.0%)	NR[‡]	503 (66.7%)	
Treatment started after policy measures effective date (April 9, 2020), n (%)						
No (before April 9, 2020)	0 (0.0%)	153 (38.8%)	70 (70.0%)	12 (100.0%)	232 (30.8%)	<0.0001
Yes (on/after April 9, 2020)	248 (100.0%)	241 (61.2%)	30 (30.0%)	NR[‡]	522 (69.2%)	
Treatment started in COVID period by wave, n (%)						
Pre-COVID (Jan 22, 2020 to Mar 10, 2020)	0 (0.0%)	138 (35.0%)	63 (63.0%)	12 (100.0%)	201 (26.7%)	<0.0001
Wave 1, wildtype (Mar 11, 2020 to Jul 17, 2020)	42 (16.9%)	58 (14.7%)	31 (31.0%)	NR[‡]	132 (17.5%)	
Wave 2, wildtype (Jul 18, 2020 to Mar 04, 2021)	82 (33.1%)	84 (21.3%)	6 (6.0%)	NR[‡]	174 (23.1%)	
Wave 3, Alpha (Mar 05, 2021 to Jul 22, 2021)	62 (25.0%)	62 (15.7%)	NR[‡]	NR[‡]	128 (17.0%)	
Wave 4, Delta (Jul 23, 2021 to Nov 03, 2021)	43 (17.3%)	38 (9.6%)	NR[‡]	0 (0.0%)	85 (11.3%)	
Wave 5, Omicron (Nov 04, 2021 to Dec 31, 2021)	19 (7.7%)	14 (3.6%)	NR[‡]	0 (0.0%)	34 (4.5%)	

[†] Excluding 3 switching groups (n=17) due to small numbers: EXT to STD, EXT to STD to EXT, and STD to EXT to STD to EXT. [‡] Cells with <6 were not reported (NR). To prevent back-calculation, numbers were combined with no prior approval submitted for extended dosing interval modification, before policy measures effective date, and pre-COVID.



Figure S3 Kaplan-Meier Plots for overall survival by treatment group for original cohort for switching and non-switching groups.

https://dx.doi.org/10.21037/ace-24-16